← Back to Search

Radiation Therapy

Stereotactic Radiation for Pancreatic Cancer

Phase 1 & 2
Waitlist Available
Led By Stanley Liauw, MD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months after treatment
Awards & highlights

Study Summary

This study is evaluating whether a higher dose of radiation can be tolerated for pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months after treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months after treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Identify the appropriate dose for treatment of unresected carcinoma of the ampulla or pancreas
Maximum Tolerated Dose (phase 1)
Secondary outcome measures
Change in patient reported outcomes using FACT-Hepatobiliary (FACT-Hep) quality of life questionnaire.
Change in patient reported pain score using visual analog scale
Number of patients eligible for surgery to remove tumor after treatment
+2 more

Side effects data

From 2019 Phase 1 & 2 trial • 160 Patients • NCT02052648
67%
Hypotension
67%
Nausea
67%
Constipation
67%
Cough
33%
Vision blurred
33%
Seizure
33%
Fatigue
33%
Traumatic haematoma
33%
Mood altered
33%
Abdominal pain
33%
Pain in extremity
33%
Hyperchloraemia
33%
Micturition urgency
33%
Pollakiuria
33%
Urinary incontinence
33%
Nocturia
33%
Pain
33%
Rectal haemorrhage
33%
Hypokalaemia
33%
Proctitis
33%
Sepsis
33%
Haemorrhoids
33%
Hyperglycaemia
33%
Decreased appetite
33%
Vomiting
33%
Dyspnoea
33%
Pyrexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Phase 1 Dose Level 1
Phase 2 Cohort 2b
Phase 2 Cohort 2a
Phase 1 Dose Level 2
Phase 1 Dose Level 3
Phase 2 Cohort 2c

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic RadiationExperimental Treatment1 Intervention
Escalating doses of SBRT in three doses over ten days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Radiation
2014
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,004 Previous Clinical Trials
819,760 Total Patients Enrolled
Stanley Liauw, MDPrincipal InvestigatorUniversity of Chicago
1 Previous Clinical Trials
74 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
2009. "Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01342354.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top